QQQ   360.09 (+0.51%)
AAPL   173.01 (+1.05%)
MSFT   320.93 (+1.64%)
META   305.64 (+1.81%)
GOOGL   133.88 (+2.31%)
AMZN   129.19 (+1.63%)
TSLA   250.63 (+0.16%)
NVDA   445.43 (+2.40%)
NIO   8.81 (-2.54%)
BABA   86.38 (-0.42%)
AMD   102.73 (-0.09%)
T   14.70 (-2.13%)
F   12.26 (-1.29%)
MU   67.67 (-0.53%)
CGC   0.74 (-6.02%)
GE   108.55 (-1.81%)
DIS   81.48 (+0.53%)
AMC   8.20 (+2.63%)
PFE   33.84 (+2.02%)
PYPL   58.48 (+0.03%)
NFLX   379.74 (+0.57%)
QQQ   360.09 (+0.51%)
AAPL   173.01 (+1.05%)
MSFT   320.93 (+1.64%)
META   305.64 (+1.81%)
GOOGL   133.88 (+2.31%)
AMZN   129.19 (+1.63%)
TSLA   250.63 (+0.16%)
NVDA   445.43 (+2.40%)
NIO   8.81 (-2.54%)
BABA   86.38 (-0.42%)
AMD   102.73 (-0.09%)
T   14.70 (-2.13%)
F   12.26 (-1.29%)
MU   67.67 (-0.53%)
CGC   0.74 (-6.02%)
GE   108.55 (-1.81%)
DIS   81.48 (+0.53%)
AMC   8.20 (+2.63%)
PFE   33.84 (+2.02%)
PYPL   58.48 (+0.03%)
NFLX   379.74 (+0.57%)
QQQ   360.09 (+0.51%)
AAPL   173.01 (+1.05%)
MSFT   320.93 (+1.64%)
META   305.64 (+1.81%)
GOOGL   133.88 (+2.31%)
AMZN   129.19 (+1.63%)
TSLA   250.63 (+0.16%)
NVDA   445.43 (+2.40%)
NIO   8.81 (-2.54%)
BABA   86.38 (-0.42%)
AMD   102.73 (-0.09%)
T   14.70 (-2.13%)
F   12.26 (-1.29%)
MU   67.67 (-0.53%)
CGC   0.74 (-6.02%)
GE   108.55 (-1.81%)
DIS   81.48 (+0.53%)
AMC   8.20 (+2.63%)
PFE   33.84 (+2.02%)
PYPL   58.48 (+0.03%)
NFLX   379.74 (+0.57%)
QQQ   360.09 (+0.51%)
AAPL   173.01 (+1.05%)
MSFT   320.93 (+1.64%)
META   305.64 (+1.81%)
GOOGL   133.88 (+2.31%)
AMZN   129.19 (+1.63%)
TSLA   250.63 (+0.16%)
NVDA   445.43 (+2.40%)
NIO   8.81 (-2.54%)
BABA   86.38 (-0.42%)
AMD   102.73 (-0.09%)
T   14.70 (-2.13%)
F   12.26 (-1.29%)
MU   67.67 (-0.53%)
CGC   0.74 (-6.02%)
GE   108.55 (-1.81%)
DIS   81.48 (+0.53%)
AMC   8.20 (+2.63%)
PFE   33.84 (+2.02%)
PYPL   58.48 (+0.03%)
NFLX   379.74 (+0.57%)
NYSE:GKOS

Glaukos (GKOS) Stock Forecast, Price & News

$71.32
-3.93 (-5.22%)
(As of 03:52 PM ET)
Compare
Today's Range
$70.09
$74.80
50-Day Range
$71.77
$78.37
52-Week Range
$40.45
$80.28
Volume
537,298 shs
Average Volume
439,483 shs
Market Capitalization
$3.47 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$79.00

Glaukos MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
11.5% Upside
$79.00 Price Target
Short Interest
Bearish
13.57% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.90
Upright™ Environmental Score
News Sentiment
0.00mentions of Glaukos in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$9.74 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.26) to ($2.01) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.81 out of 5 stars

Medical Sector

902nd out of 969 stocks

Surgical & Medical Instruments Industry

93rd out of 100 stocks


GKOS stock logo

About Glaukos (NYSE:GKOS) Stock

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent, iStent inject, iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite, an implantable device intended to reduce the intraocular pressure of the eye; and iDose TR, a targeted injectable implant based on its micro-scale device-platform that is designed to deliver therapeutic levels of medication. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo California.

GKOS Price History

GKOS Stock News Headlines

Glaukos (NYSE:GKOS) Upgraded to Hold by StockNews.com
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Glaukos (NYSE:GKOS) Stock Rating Reaffirmed by Stifel Nicolaus
Stifel Nicolaus Reaffirms Their Buy Rating on Glaukos (GKOS)
66,000% upside on tiny biotech?
The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.
Medical Device Aug 2 Earnings Roster: MCK, FMS & GKOS
Analyst Ratings for Glaukos
These 2 Soaring Stocks Finished the Week Strong
Where Glaukos Stands With Analysts
Glaukos (GKOS) Gets a Buy from BTIG
See More Headlines
Receive GKOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Glaukos and its competitors with MarketBeat's FREE daily newsletter.

GKOS Company Calendar

Last Earnings
8/02/2023
Today
10/02/2023
Next Earnings (Estimated)
11/01/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
N/A
Sector
Medical
Employees
783
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$79.00
High Stock Price Forecast
$90.00
Low Stock Price Forecast
$48.00
Forecasted Upside/Downside
+11.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
9 Analysts

Profitability

Net Income
$-99,190,000.00
Pretax Margin
-42.15%

Debt

Sales & Book Value

Annual Sales
$296.79 million
Book Value
$11.11 per share

Miscellaneous

Free Float
44,855,000
Market Cap
$3.45 billion
Optionable
Optionable
Beta
1.22
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Mr. Thomas William Burns (Age 62)
    Chairman & CEO
    Comp: $1.5M
  • Mr. Joseph E. GilliamMr. Joseph E. Gilliam (Age 47)
    Pres & COO
    Comp: $974.59k
  • Mr. Alex R. Thurman (Age 53)
    Sr. VP & CFO
    Comp: $373.4k
  • Mr. Chris M. Calcaterra (Age 63)
    Exec. VP of Global Commercial Operations
    Comp: $198.66k
  • Dr. Tomas Navratil Ph.D. (Age 46)
    Chief Devel. Officer
    Comp: $721.51k
  • Dr. Mory Gharib Ph.D.
    Co-Founder
  • Mr. Christopher William Lewis
    VP of Investor Relations & Corp. Affairs
  • Ms. Diane W. Biagianti (Age 60)
    Sr. VP & Gen. Counsel
  • Ms. Diana A. Scherer
    VP of Compliance & Deputy Gen. Counsel
  • Ms. Michele M. Allegretto
    Sr. VP of HR













GKOS Stock - Frequently Asked Questions

Should I buy or sell Glaukos stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Glaukos in the last twelve months. There are currently 3 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" GKOS shares.
View GKOS analyst ratings
or view top-rated stocks.

What is Glaukos' stock price forecast for 2023?

9 brokerages have issued 12 month price objectives for Glaukos' stock. Their GKOS share price forecasts range from $48.00 to $90.00. On average, they predict the company's share price to reach $79.00 in the next year. This suggests a possible upside of 11.5% from the stock's current price.
View analysts price targets for GKOS
or view top-rated stocks among Wall Street analysts.

How have GKOS shares performed in 2023?

Glaukos' stock was trading at $43.68 at the start of the year. Since then, GKOS shares have increased by 62.2% and is now trading at $70.84.
View the best growth stocks for 2023 here
.

Are investors shorting Glaukos?

Glaukos saw a increase in short interest in August. As of August 31st, there was short interest totaling 6,480,000 shares, an increase of 9.6% from the August 15th total of 5,910,000 shares. Based on an average daily trading volume, of 461,700 shares, the days-to-cover ratio is currently 14.0 days.
View Glaukos' Short Interest
.

When is Glaukos' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our GKOS earnings forecast
.

How were Glaukos' earnings last quarter?

Glaukos Co. (NYSE:GKOS) announced its quarterly earnings results on Wednesday, August, 2nd. The medical instruments supplier reported ($0.55) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.02. The medical instruments supplier had revenue of $80.40 million for the quarter, compared to analyst estimates of $74.73 million. Glaukos had a negative trailing twelve-month return on equity of 19.53% and a negative net margin of 42.61%. The company's quarterly revenue was up 10.6% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.83) EPS.

What guidance has Glaukos issued on next quarter's earnings?

Glaukos issued an update on its FY 2023 earnings guidance on Wednesday, August, 2nd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $304.00 million-$308.00 million, compared to the consensus revenue estimate of $298.69 million.

What is Thomas W. Burns' approval rating as Glaukos' CEO?

10 employees have rated Glaukos Chief Executive Officer Thomas W. Burns on Glassdoor.com. Thomas W. Burns has an approval rating of 100% among the company's employees. This puts Thomas W. Burns in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Glaukos own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Glaukos investors own include NVIDIA (NVDA), Marvell Technology (MRVL), PTC Therapeutics (PTCT), PayPal (PYPL), QUALCOMM (QCOM), Alibaba Group (BABA), Teladoc Health (TDOC), Intel (INTC), Advanced Micro Devices (AMD) and Boeing (BA).

When did Glaukos IPO?

(GKOS) raised $76 million in an initial public offering (IPO) on Thursday, June 25th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. J.P. Morgan, BofA Merrill Lynch and Goldman Sachs served as the underwriters for the IPO and William Blair and Cantor Fitzgerald were co-managers.

What is Glaukos' stock symbol?

Glaukos trades on the New York Stock Exchange (NYSE) under the ticker symbol "GKOS."

How do I buy shares of Glaukos?

Shares of GKOS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Glaukos' stock price today?

One share of GKOS stock can currently be purchased for approximately $70.84.

How much money does Glaukos make?

Glaukos (NYSE:GKOS) has a market capitalization of $3.45 billion and generates $296.79 million in revenue each year. The medical instruments supplier earns $-99,190,000.00 in net income (profit) each year or ($2.64) on an earnings per share basis.

How many employees does Glaukos have?

The company employs 783 workers across the globe.

How can I contact Glaukos?

Glaukos' mailing address is 229 AVENIDA FABRICANTE, SAN CLEMENTE CA, 92672. The official website for the company is www.glaukos.com. The medical instruments supplier can be reached via phone at (949) 367-9600, via email at investors@glaukos.com, or via fax at 949-367-9984.

This page (NYSE:GKOS) was last updated on 10/2/2023 by MarketBeat.com Staff

My Account -